21 March 2014

AquaBounty Technologies
("AquaBounty" or "the Company")

Preliminary Results for the year ended 31 December 2013
and Notification of AGM

AquaBounty Technologies, Inc. (AIM: ABTX), a biotechnology company focused on enhancing productivity in the aquaculture market, announces the Company's preliminary financial results for the year ended 31 December 2013 and the date of its 2014 Annual General Meeting ("AGM").

Financial and operational summary:

- U.S. Food and Drug Administration ("FDA") completed the public comment period on its draft Environmental Assessment and Preliminary Finding of No Significant Impact for AquAdvantage® Salmon ("AAS");
- In November 2013, Environment Canada, the agency of the Government of Canada with responsibility for regulating environmental policies and issues, decided that AAS is not harmful to the environment or human health when produced in contained facilities;
- Completed an equity subscription of US$6.0 million;
- Operating spend was higher at US$4.9 million (2012: US$4.4 million) as the Company invested in new research projects;
- Net loss increased to US$4.7 million (2012: US$4.4 million net loss);
- Cash used during the year, net of new equity provided, increased to US$4.2 million (2012: US$3.0 million); and
- Cash at 31 December 2013 was US$1.9 million.

Post period-end developments:

- In January 2014, Intrexon Corporation, the Company's majority shareholder, agreed to undertake a subscription for new common shares of US$10.0 million (approximately £6.0 million) before expenses; and
- In March 2014, the Company began preparations to register its common shares with the U.S. Securities and Exchange Commission and to seek a listing on NASDAQ.

Ron Stotish, Chief Executive Officer of AquaBounty, said: "We are pleased that the Company achieved two significant milestones in the year: firstly, the FDA completed the public comment period on its draft Environmental Assessment and preliminary Finding of No Significant Impact for AquAdvantage® Salmon; and secondly, Environment Canada decided that AAS is not harmful to the environment or human health when produced in contained facilities.

"While we cannot be certain about the timing, the Board is working on the assumption that approval will be forthcoming in 2014. The strong support provided by Intrexon provides the Company with sufficient financial resources to fund our operations through mid-2015 and carry out appropriate preparations for commercial development once AAS receives approval."

For further information, please contact:

AquaBounty Technologies	+1 978 648 6000
David Frank, Chief Financial Officer	

Oriel Securities Limited Giles Balleny	+44 (0)20 7710 7499
Luther Pendragon Harry Chathli, Claire Norbury	+44 (0)20 7618 9100

AGM Notification

AquaBounty will be holding its Annual General Meeting on 8 July 2014 at 08:30 a.m. (Eastern Daylight Time) at the Millennium Bostonian Hotel, 26 North Street, Boston, Massachusetts. Stockholders of record on 6 June 2014 shall be entitled to vote at the AGM.

Chairman's Statement

Throughout 2013, AquaBounty operated under the expectation that the approval of its New Animal Drug Application ("NADA") for AquAdvantage® Salmon ("AAS") from the U.S. Food and Drug Administration ("FDA") would be forthcoming. This assumption was based on the release of the draft Environmental Assessment ("EA") and preliminary Finding of No Significant Impact ("FONSI") by the FDA in December 2012. By comparison with other NADA approvals, it appears that the process in this case is all but complete. The Company continues to believe the FDA will conclude its review and approve our application, and thus has begun to prepare for commercial production of AAS.

FDA approval process

I reported last year that the FDA had been considering its responsibilities under the U.S. National Environmental Policy Act and preparing its EA for AAS. This occurred on 26 December 2012, along with a draft FONSI, meaning that AAS is safe for the environment under its conditions of use. Both the EA and the FONSI were then subject to a period of open public comment that expired on 26 April 2013. Since that time, we believe that the FDA has been working to finalize the EA and FONSI in conjunction with the approval of the NADA for AAS. Though it is our view that the conclusion of this process is near, we have not received specific guidance from the FDA regarding the timing for an approval.

Production approval in Canada

In November, Environment Canada, the agency of the Government of Canada with responsibility for regulating environmental policies and issues, decided that AAS is not harmful to human health nor to the environment when produced in contained facilities. The publication of the Significant New Activity Notice by the Canadian government recognizes that our hatchery, which produces sterile, all-female eggs, is no longer solely a research facility but can produce eggs on a commercial scale without harm to the environment or human health.

Operations

AquaBounty began 2013 with just US$360,000 of cash and this was augmented by a short-term bridge loan from our new major shareholder, Intrexon Corporation ("Intrexon"), for US$500,000 to fund operations until a larger fundraise could be completed. Given the positive news of the issuance of the EA and FONSI, the Company decided to raise additional funds sufficient to continue operations for another year and also implement new research programs under its Exclusive Channel Collaboration ("ECC") agreement with Intrexon. It was considered in the best interests of all shareholders to raise US$6.0 million by means of a limited equity placing to certain existing shareholders and this was completed on 15 March 2013.

During the year, management continued its existing research and development programs through an extension of the Contract Research Agreement with the Center for Aquaculture Technologies and commenced work on two new research projects under the ECC with Intrexon. In Panama, the Company extended its lease on its production site for an additional two years and commenced field trials with a new commercial-scale batch of AAS at the site in May. As with the previous field trials, this batch of fish is thriving and performing in-line with the Company's expectations, once again clearly demonstrating the benefits of this product. Preliminary discussions with prospective producers within the USA and elsewhere have revealed considerable interest in commencing commercial production of AAS.

Operating expenses for the year amounted to US$4.9 million (2012: US$4.4 million). The increase was primarily due to increased spending on research activities. The net loss for the year was higher at US$4.7 million (2012: US$4.4 million) and included a gain of US$0.2 million due to an adjustment to a long-term, royalty-based financing instrument. Cash used for the year, net of new equity and bridge funding, was higher at US$4.0 million (2012: US$3.2 million). Funds available at the year-end amounted to US$1.9 million.

Intrexon Corporation

Intrexon became the Company's largest shareholder in 2012 after purchasing all of the common shares then held by Linnaeus Capital Partners. Shortly thereafter, Intrexon agreed to provide AquaBounty with a US$500,000 bridge loan to fund operations until a larger funding could be put in place. The loan, plus interest, was repaid from the proceeds of the Company's fundraising in March 2013. Intrexon's participation in the funding round increased their ownership in AquaBounty to 53.75% and thus they became the majority shareholder with four of the seven seats on our Board.

Post period-end activities

In January 2014 Intrexon agreed to undertake a subscription for new common shares to the value of US$10.0 million (approximately £6.0 million) before expenses. The subscription price was 31.5 pence per share (US$0.5252) and the aggregate number of common shares subscribed was 19,040,366. The transaction closed on 20 March 2014 with net proceeds to the Company of approximately US$9.7 million. This has further increased Intrexon's shareholding to 59.85%.

In March, the Company began preparations to register its common shares with the U.S. Securities and Exchange Commission and to seek a listing on NASDAQ. We believe this will allow for greater liquidity and access for investors to our shares.

Outlook

Although we cannot be certain about the timing, the Board is working on the assumption that approval of the NADA will be forthcoming in 2014, following the finalization of the EA and FONSI. The strong support provided by Intrexon allows the Company to look ahead to post-approval activities and carry out appropriate preparations. Our financial resources are now sufficient to fund operations through mid-2015 and, once AAS is approved for commercial development, more robust plans for commercialization will be finalized.

R J Clothier

Consolidated balance sheets

As of 31 December	**2013**	2012
ASSETS		
Current assets:		
Cash and cash equivalents	**$1,875,749**	$348,521
Certificate of deposit	**13,431**	14,405
Other receivables	**78,455**	24,429
Prepaid expenses and other assets	**220,888**	127,104
Total current assets	**2,188,523**	514,459
Property, plant and equipment, net	**1,016,843**	1,131,214
Definite lived intangible assets, net	**141,779**	102,504
Indefinite lived intangible assets	**191,800**	191,800
Other assets	**21,628**	21,628
Total assets	**$3,560,573**	$1,961,605
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
Current liabilities:		
Accounts payable and accrued liabilities	**$704,028**	$435,849
Current debt	_	270,560
Total current liabilities	**704,028**	706,409
Long-term debt, net of current portion	**2,359,653**	2,034,907
Total liabilities	**3,063,681**	2,741,316
Commitments and contingencies		
Stockholders' equity (deficit):		
Common stock, $0.001 par value, 200,000,000 shares authorized; 125,305,471 (2012: 102,255,688) shares outstanding	**125,305**	102,256
Additional paid-in capital	**77,582,210**	71,733,509
Accumulated other comprehensive loss	**(566,310)**	(660,201)
Accumulated deficit	**(76,644,313)**	(71,955,275)
Total stockholders' equity (deficit)	**496,892**	(779,711)
Total liabilities and stockholders' equity (deficit)	**$3,560,573**	$1,961,605

Consolidated statements of operations and comprehensive loss

Years ended 31 December	**2013**	2012
COSTS AND EXPENSES		
Sales and marketing	**$678,153**	$581,954
Research and development	**1,895,056**	1,628,593
General and administrative	**2,302,279**	2,101,260
Restructuring charge	—	93,780
Total costs and expenses	**4,875,488**	4,405,587
OPERATING LOSS	**(4,875,488)**	(4,405,587)
OTHER INCOME (EXPENSE):		
Gain on royalty based financing instrument	186,980	—
Interest and other expense, net	**(530)**	(9,026)
Total other income (expense)	**186,450**	(9,026)
NET LOSS	**$(4,689,038)**	$(4,414,613)
OTHER COMPREHENSIVE INCOME (LOSS):		
Foreign currency translation gain (loss)	**93,891**	(9,397)
Total other comprehensive income (loss)	**93,891**	(9,397)
COMPREHENSIVE LOSS	**$(4,595,147)**	$(4,424,010)
Basic and diluted net loss per share	**$(0.04)**	$(0.05)
Weighted average number of common shares – basic and diluted	**120,613,246**	94,701,028

Consolidated statements of changes in stockholders' equity (deficit)

	Common stock issued and outstanding	Par value	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit	Total
Balance at 31 December 2011	68,780,968	$68,781	$69,700,198	$(650,804)	$(67,540,662)	$1,577,513
Net loss					(4,414,613)	(4,414,613)
Other comprehensive loss				(9,397)		(9,397)
Issuance of common stock, net of expenses	33,277,870	33,278	1,709,200			1,742,478
Share based compensation – common stock	196,850	197	23,353			23,550
Share based compensation – options			300,758			300,758
Balance at 31 December 2012	102,255,688	$102,256	$71,733,509	$(660,201)	$(71,955,275)	$(779,711)
Net loss					**(4,689,038)**	**(4,689,038)**
Other comprehensive income				**93,891**		**93,891**
Issuance of common stock, net of expenses	**22,883,295**	**22,883**	**5,702,724**			**5,725,607**
Exercise of options for common stock	**29,500**	**29**	**3,971**			**4,000**
Exercise of options for common stock - cashless	**71,771**	**72**	**(72)**			**—**
Share based compensation – common stock	**65,217**	**65**	**22,747**			**22,812**
Share based compensation – options			**119,331**			**119,331**
Balance at 31 December 2013	**125,305,471**	**$125,305**	**$77,582,210**	**$(566,310)**	**$(76,644,313)**	**$496,892**

Consolidated statements of cash flows

Years ended 31 December	**2013**	2012
OPERATING ACTIVITIES		
Net loss	**$(4,689,038)**	$(4,414,613)
Adjustment to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	**147,101**	225,416
Share-based compensation	**142,143**	324,308
Amortization (accretion) of discount (premium) on corporate bonds	**—**	(326)
Loss on disposed assets	**—**	5,776
Gain on royalty based financing instrument	**(186,980)**	—
Changes in operating assets and liabilities:		
Other receivables	**(57,264)**	90,907
Prepaid expenses and other assets	**(94,935)**	121,481
Accounts payable and accrued liabilities	**281,345**	(68,404)
Net cash used in operating activities	**(4,457,628)**	(3,715,455)
INVESTING ACTIVITIES		
Purchases of equipment	**(99,500)**	(52,841)
Paid out (reinvested) interest on certificate of deposit	**(6)**	6
Payment of patent costs	**(42,249)**	(69,210)
Net cash used in investing activities	**(141,755)**	(122,045)
FINANCING ACTIVITIES		
Proceeds from issuance of bridge loan	**300,000**	200,000
Repayment of bridge loan	**(500,000)**	—
Proceeds from issuance of long-term debt	**665,199**	678,657
Repayment of other term debt	**(68,327)**	(68,575)
Proceeds from issuance of common stock, net	**5,725,607**	1,742,478
Proceeds from exercise of stock options	**4,000**	—
Net cash provided by financing activities	**6,126,479**	2,552,560
Effect of exchange rate changes on cash and cash equivalents	**132**	2,481
Net increase (decrease) in cash and cash equivalents	**1,527,228**	(1,282,459)
Cash and cash equivalents at beginning of year	**348,521**	1,630,980
Cash and cash equivalents at end of year	**$1,875,749**	$348,521
SUPPLEMENTAL CASH FLOW INFORMATION		
Interest paid in cash	**$4,223**	$4,414